Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Crisaborole Ointment
DRUG
3 trials
Sponsors
Pfizer
, Sun Yat-sen University
Conditions
Atopic Dermatitis
Cetuximab
Metastatic Colorectal Cancer
Skin Toxicity
Stasis Dermatitis
Phase 2
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Completed
NCT04091087
Pfizer
Stasis Dermatitis
Start: 2020-06-26
End: 2021-10-19
Updated: 2022-05-02
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
NCT06118047
Sun Yat-sen University
Cetuximab, Metastatic Colorectal Cancer, Skin Toxicity
Start: 2023-08-01
End: 2025-12-31
Target: 33
Updated: 2023-11-07
Phase 3
Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis
Completed
NCT04360187
Pfizer
Atopic Dermatitis
Start: 2020-07-27
End: 2021-09-08
Updated: 2022-06-07
Related Papers
Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
2024-05-15
2 citations
Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
2024-02-08
11 citations
434 Efficacy and safety of crisaborole ointment, 2%, in Chinese and Japanese pediatric patients aged 2–17 years with mild-to-moderate atopic dermatitis
British Journal of Dermatology
2023-06-01
Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis
The Journal of Dermatology
2023-05-08
13 citations